Romero-Aroca P. Managing diabetic macular edema: The leading cause of diabetes blindness. World J Diabetes. 2011;2(6):98-104.
Brown D, Wolf S, Garweg JG, et al. Brolucizumab for the treatment of visual impairment due to diabetic macular edema: 52-week results from the KESTREL & KITE studies. Presented at: The Association for Research in Vision and Ophthalmology (ARVO) 2021 Annual Meeting. May 2021.
Beovu [summary of product characteristics] Basel, Switzerland. Novartis: 2020.
Eylea [summary of product characteristics] Berlin, Germany. Bayer AG: 2014.
Data on file. KESTREL clinical trial protocol (CRTH258B2301). Novartis, 2021.
Data on file. KITE clinical trial protocol (CRTH258B2302). Novartis, 2021.